Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazhu Rhodiola injection for coronary heart disease with angina
ChiCTR2000036213Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Dazhuhongjingtian in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Incidence of major adverse cardiovascular events. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
Dazhuhongjingtian
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on ChiCTR2000036213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036213.